Research presented at ADLM 2026 indicates immunoassays may significantly underestimate HbA1c in patients with sickle cell trait, suggesting HPLC offers more reliable diabetes screening for populations with hemoglobin variants.
ALZpath and Alamar Biosciences have expanded their partnership, granting Alamar commercial rights to use ALZpath’s pTau217 antibody in clinical blood tests for Alzheimer’s disease.
A new NIH-funded study finds that elevated circular RNAs in blood may predict Alzheimer’s symptoms years in advance, outperforming current blood tests in forecasting disease progression.
A new study in The Journal of Nuclear Medicine reports that a noninvasive DNA blood test can help select advanced prostate cancer patients most likely to benefit from 223Ra radiopharmaceutical therapy and monitor treatment response.
The assay from Seegene USA simultaneously detects and differentiates herpes simplex virus, varicella-zoster virus, and monkeypox virus.
The expanded commercialization agreement aims to increase availability of the GlycoKnow Ovarian laboratory-developed test through Aranscia's clinical workflow and technology platforms.
Castle Biosciences’ AdvanceAD-Tx gene expression test for atopic dermatitis has received New York State approval, enabling clinicians to better guide systemic therapy selection for patients with moderate-to-severe disease.
The assay measures lipoprotein(a) levels in molar units to improve cardiovascular risk assessment and standardization across laboratories.
A blood-based biomarker test enabled primary care physicians to diagnose Alzheimer’s with up to 93% accuracy, comparable to specialists, according to data from a 1,300-patient study presented at AAIC 2026.
Researchers from Charité – Universitätsmedizin Berlin report that steatotic liver disease subtypes often shift over time, with 36% of MetALD patients reclassified within six months, suggesting a need for dynamic disease monitoring.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.